Literature DB >> 15355910

Prognostic value of combined "triple"-reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients.

Ralf Kurek1, German Nunez, Nikolaos Tselis, Lutz Konrad, Thomas Martin, Sandra Roeddiger, Gerd Aumüller, Nikolaos Zamboglou, Daniel W Lin, Ulf W Tunn, Heiner Renneberg.   

Abstract

PURPOSE: We present the largest study of both peripheral blood and lymph node samples examining the utility of reverse transcription-polymerase chain reaction (RT-PCR) for established molecular markers as a diagnostic tool in the molecular staging of prostate cancer patients undergoing radical prostatectomy. EXPERIMENTAL
DESIGN: Peripheral blood from 358 patients was obtained before radical prostatectomy. Corresponding obturatory lymph node samples were collected from 153 of these patients. Nested RT-PCR for prostate-specific antigen (PSA), human kallikrein 2 (hK2), and prostate-specific membrane antigen (PSMA) were performed on cDNA from peripheral blood. The lymph node cDNA was analyzed for PSA und hK2 expression.
RESULTS: RT-PCR in peripheral blood was positive in 124 (34.6%) of 358 samples for PSA, 215 (60.1%) of 358 for PSMA, and 97 (27.1%) of 358 for hK2. Comparison of positive RT-PCR rates of pT(2) and pT(3) tumors in corresponding peripheral blood for PSA, PSMA, and hK2 were 31.9 and 40.0%, 58.8 and 62.5%, and 26.9 and 27.5%, respectively. Histopathologically, cancer-free lymph node samples were positive in RT-PCR for PSA and hK2 in 70 (49.6%) of 141 and 89 (63.2%) of 141 of cases. All histologically positive lymph node samples (n = 12, pN+) were positive for PSA RT-PCR. PSA RT-PCR alone, as well as combined PSA/PSMA RT-PCR evaluation, in peripheral blood showed a significant association with grading. PSA RT-PCR lymph node-negative samples were significantly less likely positive in their corresponding peripheral blood RT-PCR sample.
CONCLUSIONS: Although the preoperative PSA RT-PCR in peripheral blood correlated with the grading of prostate cancer, no combination of RT-PCR results using "triple" markers (PSA, hK2, PSMA) in peripheral blood and/or lymph nodes yielded additional preoperative staging information.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15355910     DOI: 10.1158/1078-0432.CCR-1004-03

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  8 in total

Review 1.  Tumor markers in prostate cancer I: blood-based markers.

Authors:  Shahrokh F Shariat; Axel Semjonow; Hans Lilja; Caroline Savage; Andrew J Vickers; Anders Bjartell
Journal:  Acta Oncol       Date:  2011-06       Impact factor: 4.089

2.  Utility of tissue microarrays for profiling prognostic biomarkers in clinically localized prostate cancer: the expression of BCL-2, E-cadherin, Ki-67 and p53 as predictors of biochemical failure after radical prostatectomy with nested control for clinical and pathological risk factors.

Authors:  Joseph Nariculam; Alex Freeman; Simon Bott; Phillipa Munson; Noriko Cable; Nicola Brookman-Amissah; Magali Williamson; Roger S Kirby; John Masters; Mark Feneley
Journal:  Asian J Androl       Date:  2008-12-01       Impact factor: 3.285

3.  Assays for prostate cancer : changing the screening paradigm?

Authors:  Jens Hansen; Michael Rink; Markus Graefen; Shahrokh Shariat; Felix K-H Chun
Journal:  Mol Diagn Ther       Date:  2013-02       Impact factor: 4.074

4.  Correlation of MR imaging and MR spectroscopic imaging findings with Ki-67, phospho-Akt, and androgen receptor expression in prostate cancer.

Authors:  Amita Shukla-Dave; Hedvig Hricak; Nicole M Ishill; Chaya S Moskowitz; Marija Drobnjak; Victor E Reuter; Kristen L Zakian; Peter T Scardino; Carlos Cordon-Cardo
Journal:  Radiology       Date:  2009-03       Impact factor: 11.105

5.  Real-time quantitative RT-PCR assessment of PIM-1 and hK2 mRNA expression in benign prostate hyperplasia and prostate cancer.

Authors:  Hui-chan He; Xue-cheng Bi; Zhi-wei Zheng; Qi-shan Dai; Zhao-Dong Han; Yu-Xiang Liang; Yong-Kang Ye; Guo-hua Zeng; Gang Zhu; Wei-de Zhong
Journal:  Med Oncol       Date:  2008-11-12       Impact factor: 3.064

6.  Isolation and characterization of circulating tumor cells in prostate cancer.

Authors:  Elan Diamond; Guang Yu Lee; Naveed H Akhtar; Brian J Kirby; Paraskevi Giannakakou; Scott T Tagawa; David M Nanus
Journal:  Front Oncol       Date:  2012-10-11       Impact factor: 6.244

Review 7.  Novel tools for prostate cancer prognosis, diagnosis, and follow-up.

Authors:  Andreas Dimakakos; Athanasios Armakolas; Michael Koutsilieris
Journal:  Biomed Res Int       Date:  2014-05-04       Impact factor: 3.411

8.  Overexpression of prostate specific membrane antigen by canine hemangiosarcoma cells provides opportunity for the molecular detection of disease burdens within hemorrhagic body cavity effusions.

Authors:  Matthew Dowling; Jonathan Samuelson; Bahaa Fadl-Alla; Holly C Pondenis; Mark Byrum; Anne M Barger; Timothy M Fan
Journal:  PLoS One       Date:  2019-01-02       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.